Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Ipsen has discontinued all active tazemetostat clinical trials and expanded access programs due to the emergence of a clinically unfavorable benefit risk profile for tazemetostat in combination with lenalidomide and rituximab.

Conditions

Solid Tumor
ARID1A Gene Mutation

Interventions

DRUG: Tazemetostat

Sponsor

Prisma Health-Upstate

Collaborators

[object Object]